David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines some highlights in the field of myelodysplastic syndromes (MDS) from the ASH 2024 meeting. Unfortunately, the meeting was underwhelming regarding updates on the treatment of high-risk (HR) MDS, but some new data was presented in the lower-risk (LR) space. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть